Intervention

Dutasteride

ClinicalTrials.gov intervention label

Clinical trials15

Recruiting0

Common conditions7

Lead sponsors shown12

Clinical trials

15 shown

Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)NCT05705700 · 2023-02-01

A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomyNCT02159690 · 2014-09-01

Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate CancerNCT01547299 · 2012-03-31

Validation of Digital Morphometry for Cancer Risk in Benign Prostate BiopsiesNCT01594502 · 2011-09-01

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate CancerNCT01393730 · 2011-09-01

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate CancerNCT01342367 · 2010-12-17

ACTIVE_NOT_RECRUITING

Response of Patients on Surveillance for Prostate Cancer to DutasterideNCT01525914 · 2010-05-01

Economic Analyses of the REDUCE TrialNCT01337258 · 2010-01-01

Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate CancerNCT00985738 · 2009-09-01

Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate CancerNCT00668642 · 2007-03-01

Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate CancerNCT00553878 · 2007-03-01

Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In MenNCT00363311 · 2006-07-01

Metabolic Effects of Steroids in Obese MenNCT00983554 · 2005-06-01

Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate CancerNCT00375765 · 2005-04-01

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased RiskNCT00056407 · 2003-03-01

Common conditions

Prostate Cancer11 Neoplasms, Prostate3 Benign Prostatic Hyperplasia2 Cancer1 Insulin Resistance1 Localized Prostate Cancer1 Obesity1

Leading sponsors

GlaxoSmithKline4 Canadian Urology Research Consortium1 Endeavor Health1 Kenneth Pienta, MD1 Mary-Ellen Taplin, MD1 Masonic Cancer Center, University of Minnesota1 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1 Pfizer1 Sunnybrook Health Sciences Centre1 University of Chicago1 University of Colorado, Denver1 University of Illinois at Chicago1

Trial status mix

COMPLETED10

WITHDRAWN2

ACTIVE_NOT_RECRUITING1

TERMINATED1

UNKNOWN1

Phase mix

PHASE27

NA2

PHASE32

PHASE42

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.